SecBot SecBot

GPCR drug pipeline

$20.00
+0.8% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1/2a
Time to marketGiven that ACCG-2671 is still in Phase 1/2a, potential approval is likely many years away (probably 2029-2031 at the earliest), assuming successful clinical development.

ACCG-2671 Updated Nov 12

What to watch

ACCG-2671 is a very early-stage (Phase 1/2a) oral amylin receptor agonist for obesity. The single-dose data from September 2026 showed a ~6-day half-life, up to 3.3% body weight loss, and no serious adverse events in 31 healthy adults. The next catalyst is the MAD (multiple ascending dose) data expected in 1H 2027, which will show whether the weight-loss signal persists with repeat dosing. Investors should watch for whether the MAD data confirms a competitive profile versus other oral amylin agonists in development at Novo Nordisk and others.

Bull case
  • Oral formulation could be a major advantage over injectable obesity drugs if efficacy is confirmed in later trials.
  • The ~6-day half-life suggests potential for weekly or less-frequent oral dosing, which would be differentiated.
  • Up to 3.3% weight loss in a single-dose study in healthy non-obese adults is an encouraging early signal, especially with no serious adverse events.
Bear case
  • ACCG-2671 is very early stage (Phase 1/2a SAD only); the 3.3% weight loss came from a single dose in only 31 healthy non-obese adults, not a repeat-dose obesity study.
  • The MAD data (1H 2027) is the real test; single-dose weight loss often does not translate to sustained, clinically meaningful weight reduction.
  • The obesity market is intensely competitive with Novo Nordisk (Wegovy, oral amycretin), Eli Lilly (Zepbound, orforglipron), and others far ahead in development.
● neutral
Impact
PhasePhase 3
Time to marketPhase 3 topline data expected in 2H 2028. If successful, an FDA submission and potential approval would follow, likely in 2029-2030 at the earliest.

aleniglipron Updated Nov 12

What to watch

Watch the ObesityWeek 2026 presentation on November 15 for any incremental efficacy or tolerability detail on aleniglipron, and the three supplementary data readouts due in Q4 2026 (body composition, sleep apnea, and other analyses). The next major binary catalyst is the Phase 3 ACCOMPLISH topline data in 2H 2028, leaving a long stretch where competitive developments from Lilly's Foundayo and Novo Nordisk's oral programs will likely drive sentiment more than company-specific news.

Bull case
  • Phase 2 data showed up to 16.2% weight loss at 72 weeks, among the highest efficacy reported for any oral GLP-1, with no evidence of a weight-loss plateau and low adverse-event discontinuation rates.
  • The company has a strong cash position of $1.24 billion, funding operations and the Phase 3 program through end of 2028 without near-term dilution risk.
  • Analyst consensus is Strong Buy (21 analysts: 13 Buy, 8 Strong Buy) with a mean price target of $104.31, representing roughly 380% upside from the current ~$21 stock price.
Bear case
  • Eli Lilly's oral GLP-1 Foundayo (orforglipron) was already FDA-approved for obesity in January 2026 and is now pursuing additional approvals for sleep apnea and type 2 diabetes, creating a multi-year commercial head start.
  • The stock has collapsed roughly 78% from its 52-week high of $94.90 to ~$21, reflecting market skepticism about aleniglipron's ability to compete in the increasingly crowded GLP-1 market.
  • Phase 3 topline data is not expected until 2H 2028, leaving a long period without a binary catalyst and exposing the stock to competitive news flow from Lilly and Novo.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

ACCG-3535 Updated Nov 12

What to watch

ACCG-3535 does not appear in Structure Therapeutics' public pipeline disclosures. The company's focus is on aleniglipron (Phase 3 GLP-1 agonist) and ACCG-2671 (Phase 1/2a amylin receptor agonist). ACCG-3535 may be a discovery-stage or discontinued candidate. Investors should monitor Structure's pipeline page and quarterly filings for any mention of this compound before assigning it any value.

Bull case
  • Structure Therapeutics has a strong balance sheet with $1.24 billion in cash as of September 30, 2026, enough to fund operations through 2028, providing resources for early-stage pipeline programs.
  • The company has demonstrated expertise in oral small-molecule metabolic drug discovery, with aleniglipron showing best-in-class oral GLP-1 efficacy and ACCG-2671 showing early proof-of-concept as an oral amylin agonist.
Bear case
  • ACCG-3535 has zero public presence: no clinical trial registration, no press release, no SEC filing mention, no analyst coverage. It may be a discontinued or abandoned program.
  • Even if active, ACCG-3535 is likely preclinical or discovery-stage, meaning any clinical data is years away and the probability of eventual approval is very low.
  • Structure Therapeutics' stock has fallen sharply from its 52-week high of $94.90 to around $20.95, reflecting market skepticism about the competitive obesity drug landscape dominated by Novo Nordisk and Eli Lilly.